OCGN

Ocugen, Inc. is a forward-looking clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing groundbreaking gene therapies to address various forms of blindness. Utilizing its proprietary technologies and robust strategic partnerships, Ocugen advances a promising pipeline of innovative treatments targeting retinal diseases. With a strong commitment to addressing significant unmet needs in ocular health, the company is strategically positioned to make substantial contributions to the evolving landscape of regenerative medicine and enhance the quality of life for patients suffering from vision loss.